Aptose Biosciences Inc (APS.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2015 | 05-2014 | 05-2013 | 05-2012 | 05-2011 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | 69 | 19 | 37 | 43 | 57 |
| Accounts payable and accrued liabilities | 192 | -59 | 379 | 104 | -176 |
| Other Working Capital | 163 | -13 | -50 | 1,584 | -1,472 |
| Other Operating Activity | -9,550 | -7,814 | -5,303 | -4,070 | -4,443 |
| Operating Cash Flow | $-9,126 | $-7,867 | $-4,938 | $-2,340 | $-6,034 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -238 | -20 | N/A | 0 | -8 |
| Purchase Of Investment | N/A | -10,155 | N/A | N/A | N/A |
| Sale Of Investment | 5,718 | N/A | N/A | 0 | N/A |
| Other Investing Activity | 206 | 70 | 29 | 0 | 253 |
| Investing Cash Flow | $5,686 | $-10,105 | $29 | $0 | $245 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | -873 | N/A | N/A |
| Debt Issued | N/A | 1,537 | N/A | N/A | N/A |
| Debt Repayment | N/A | -984 | N/A | N/A | 0 |
| Common Stock Issued | 7 | 30,284 | 5,936 | N/A | 6,039 |
| Other Financing Activity | 700 | 4,381 | 169 | 1,766 | 0 |
| Financing Cash Flow | $708 | $35,219 | $5,231 | $1,766 | $6,039 |
| Exchange Rate Effect | 669 | N/A | N/A | N/A | N/A |
| Beginning Cash Position | 10,352 | 602 | 310 | 884 | 683 |
| End Cash Position | 8,289 | 17,848 | 634 | 311 | 933 |
| Net Cash Flow | $-2,732 | $17,247 | $323 | $-574 | $250 |
| Free Cash Flow | |||||
| Operating Cash Flow | -9,126 | -7,867 | -4,938 | -2,340 | -6,034 |
| Capital Expenditure | -238 | -20 | N/A | N/A | -8 |
| Free Cash Flow | -9,364 | -7,887 | -4,938 | -2,340 | -6,042 |